1015 - Prognostic factors and treatment outcomes of patients with uterine leiomyosarcoma: a retrospective study of Anatolian Society of Medical Oncology

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Gynaecologic Malignancies
Sarcoma
Presenter Ayse Durnali
Authors A. Durnali1, S. Tokluoğlu2, N. Ozdemir3, M. İnanc4, N. Alkis1, N. Zengin3, O.U. Sonmez1, M. Kucukoner5, M. Ozkan6, B. Oksuzoglu1
  • 1Department Of Medical Oncology, Ankara Dr.A.Y.Oncology Research and Education Hospital, 06200 - ANKARA/TR
  • 2Medical Oncology, Güven Hospital, Ankara/TR
  • 3Medical Oncology, numune education and research hospital, ankara/TR
  • 4Department Of Medical Oncology, Erciyes University,, kayseri/TR
  • 5Medical Oncology, Dicle University, 21280 - Diyarbakir/TR
  • 6Medical Oncology, Erciyes University Medical FacultyM.Kemal Dedeman, Oncology Hospital, TR-38039 - Kayseri/TR

Abstract

Background

Uterine leiomyosarcomas are infrequent and aggressive malignancies of female genital tract.

Methods

Data of 54 uterine leiomyosarcoma patients who were diagnosed and treated at 4 different centers from November 2000 to October 2010 were analysed retrospectively.

Results

Mean age was 50.8 years (range 34-72), and 54.9% of patients were premenapousal. According to last International Federation of Gynecology and Obstetrics (FIGO) staging system, 26 (48.1%) patients had stage I disease, 14 (25.9%) stage II, 5 (9.3%) stage III, and 9 (16.7%) stage IV. Of the 52 patients who underwent surgery, 38.4% (20 patients) were given adjuvant chemotherapy, 17.3% (9 patients) adjuvant radiotherapy, 23% (12 patients) adjuvant sequential chemotherapy and radiotherapy. Median relapse free survival (RFS) was 19 months. One, 2 and 5 year RFS were 65.2%, 42.6%, 17.2% respectively. Median overall survival (OS) was 56 months, OS after 1, 2, 5 years were 87.7%, 78.7%, 41.9% respectively. Clinicopathologic parameters that were statistically evaluated included age (<60 or ≥60 years), body mass index (80% of patients were obese or overweight), stage of disease, grade (83.3% of patients had grade 2-3 tumor), tumor size [mean 8.8cm (range 2-17.5)], mitotic activity [mean count 15.6/10 high-power fields (range 2-42)], presence of tumor cell necrosis (31 cases), presence of residual tumor after surgery (13 cases) and type of treatment procedure. After mutivariate analysis, age < 60 years (p = 0.022, HR: 4.52), low grade tumor (p = 0.019, HR: 5.18) and adjuvant treatment with sequential chemotherapy and radiotherapy after surgery (p = 0.020, HR: 0.14) were associated with longer OS.

Conclusion

Uterine sarcomas have poor prognosis. We have concluded that favorable prognostic factors affecting OS are younger age, lower grade and to be treated with adjuvant sequential chemotherapy and radiotherapy.

Disclosure

All authors have declared no conflicts of interest.